Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison

Constitutively activated mutant FLT3 has emerged as a promising target for therapy for the subpopulation of acute myeloid leukemia (AML) patients who harbor it. The small molecule inhibitor, PKC412, targets mutant FLT3 and is currently in late-stage clinical trials. However, the identification of PK...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Weisberg, Ellen, Roesel, Johannes, Furet, Pascal, Bold, Guido, Imbach, Patricia, Flörsheimer, Andreas, Caravatti, Georgio, Jiang, Jingrui, Manley, Paul, Ray, Arghya, Griffin, James D.
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2010
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3092267/
https://ncbi.nlm.nih.gov/pubmed/21779428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1947601910396505
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items